Researchers at Tokushima University discovered a novel mechanism driving autoimmune diseases like Sjögren's syndrome. The interaction between CD153-expressing CD4+ T cells and CD30 receptors on fibroblasts amplifies chronic inflammation by inducing chemokine production. Blocking this CD153-CD30 pathway significantly suppresses tissue damage, offering a promising target for future drug development.